Impact of Phone Call About Financial Reimbursement Program on Access to Cancer Clinical Trials

a study on Malignant Neoplasm Neoplasms Hematopoietic and Lymphoid Cell Neoplasm

Summary

Eligibility
for people ages 7 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion
Principal Investigator
by Hala Borno, MD
Photo of Hala Borno
Hala Borno

Description

Summary

This trial studies how well a follow-up phone call regarding financial reimbursement program (FRP) works in improving cancer patients' access to therapeutic cancer clinical trials. Follow-up phone call intervention regarding FRP may improve recruitment of cancer patients to cancer therapeutic clinical trials.

Official Title

A Pilot Feasibility Study for Improving Patient Access to Cancer Clinical Trials (iMPACT): A Financial Reimbursement Program for Patients in Cancer Therapeutic Clinical Trials

Details

There are limited financial models that address the economic hardship associated with clinical research participation and how it might restrict clinical research access. The Lazarex Foundation offers a financial reimbursement program (FRP) to help patients and caregivers cover the out-of-pocket costs associated with clinical trial participation for almost ten years. iMPACT is a pilot study to assess the overall feasibility of conducting a multi-center trial of the Lazarex sliding scale FRP among sociodemographically diverse patients of all cancer types enrolling/potentially enrolling in therapeutic clinical trials (TCTs). The study will formalize informing patients or parents/legal guardians of patients about the Lazarex sliding-scale FRP in order to evaluate whether operationalizing intensive follow-up about the Lazarex FRP improves recruitment to cancer TCTs. All patients or parents/legal guardians of patients will be offered information about the FRP at initial time of TCT discussion/consent for the iMPACT study, however, participants will be randomized 1:1 to receive an additional follow-up call about the FRP or no follow-up call (usual care). Participants who are randomized to usual care will be provided a phone number for the Lazarex Foundation that they or their parent or legal guardian may contact directly. Therefore all patients or parents/legal guardians of patients in the study have access to FRP eligibility assessment through the Lazarex Foundation. Participants or parents/legal guardians of participants will be surveyed at baseline (time of consent to iMPACT) and interviewed 30 days after consent to iMPACT. If a participant enrolls in a therapeutic clinical trial, he/she will also be given an additional survey after TCT participation and interviewed up to 90 days after TCT participation.

Keywords

Malignant Neoplasm Hematopoietic and Lymphoid Cell Neoplasm Neoplasms Cancer Educational Materials Follow-Up Care

Eligibility

For people ages 7 years and up

Inclusion Criteria:

COHORT A:

  • Eligible patients to be randomized for the iMPACT study must:
  • Carry a diagnosis of cancer
  • Patient is considered potentially eligible for a cancer therapeutic clinical trial (TCT) and is being offered an opportunity to sign an informed consent document for the cancer TCT
  • Eligible patients to receive FRP (these documents will be requested by Lazarex

Foundation, however research coordinator at site can help patient collect documents):

  1. Have a household income =< 700% of the 2018 Health and Human Services (HHS) Poverty Guidelines
  2. Willing to provide proof of household income. Acceptable proof of income documents are: first two pages of signed copy of income tax return, or if a return is not filed, a copy of the most recent pay stub, unemployment check, Supplemental Security Income (SSI), Social Security Disability (SSD), or public assistance benefit notification. If a patient is not employed, they must submit a signed letter stating their current financial situation

COHORT B:

Patients currently enrolled in a TCT or who recently completed a TCT within 90 days, and were offered, received, or are receiving FRP from the Lazarex Foundation will be approached for the longitudinal (non-randomized) follow-up portion of the study

COHORT C:

Patients with a cancer diagnosis, irrespective of TCT participation and access to FRP from the Lazarex Foundation, will be approached for the longitudinal follow-up portion of the study

Locations

  • University of California, San Francisco accepting new patients
    San Francisco California 94143 United States
  • USC / Norris Comprehensive Cancer Center accepting new patients
    Los Angeles California 90033 United States

Lead Scientist at UCSF

  • Hala Borno, MD
    Dr. Hala Borno is faculty at UCSF and an Assistant Professor in the Department of Medicine and Division of Hematology/Oncology. Dr. Borno is a medical oncologist with clinical expertise in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT03943082
Study Type
Interventional
Last Updated
Contact us about this trial